AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Stock Information for OptiNose Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OptiNose Inc.

AI-Media Partners with AudioShake to Revolutionize Live Sports Audio and AI Voice Translation
LEXI Voice is Coming: AI-Media Releases Groundbreaking AI Voice Translation at NAB 2025
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
AIM ImmunoTech Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
AI-Media Partners with the England and Wales Cricket Board for Cutting-Edge Captioning Solution
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.